Carlina-M Tablet 2.5 mg + 1000 mg is a combination oral antidiabetic medication formulated to manage type 2 diabetes mellitus in adults. It combines Linagliptin 2.5 mg, a DPP-4 inhibitor, and Metformin Hydrochloride 1000 mg, a biguanide, offering complementary mechanisms to control blood glucose levels effectively.

Metformin primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, while Linagliptin enhances incretin hormone activity, increasing insulin release in response to meals and decreasing glucagon secretion. This dual action helps lower both fasting and postprandial blood glucose levels, promoting better glycemic control.

Carlina-M is suitable for patients who require combination therapy due to insufficient glycemic control with Metformin alone, and it may be used as part of a comprehensive diabetes management plan including diet and lifestyle modifications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Antidiabetic Agent

• Combination Therapy: DPP-4 Inhibitor + Biguanide

Indications

Carlina-M Tablet is indicated for:

• Type 2 diabetes mellitus in adults

• Patients not achieving adequate glycemic control with Metformin monotherapy

• Patients who benefit from combination therapy to reduce both fasting and postprandial glucose levels

• Adjunct therapy to diet and exercise for improved glycemic control

Pharmacology

Metformin Hydrochloride:

• Reduces hepatic glucose production (gluconeogenesis)

• Increases peripheral glucose uptake and utilization

• Improves insulin sensitivity

• Does not stimulate insulin secretion, thus minimizing risk of hypoglycemia

Linagliptin:

• Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4)

• Prolongs activity of incretin hormones (GLP-1 and GIP)

• Enhances glucose-dependent insulin secretion

• Suppresses postprandial glucagon release

The combination of Linagliptin and Metformin provides synergistic glucose-lowering effects while maintaining a low risk of hypoglycemia.

Dosage and Administration

• Adults: 1 tablet daily with meals, preferably with breakfast or as prescribed by a physician

• Tablets should be swallowed whole with water

• Dosage may be adjusted based on glycemic response and patient tolerance

• Should be used in conjunction with diet and exercise to maximize therapeutic benefits

Note: Renal and hepatic function should be assessed prior to initiation and periodically during therapy.

Contraindications

• Known hypersensitivity to Linagliptin, Metformin, or any component of the formulation

• Severe renal impairment (eGFR <30 mL/min/1.73 m²)

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Hepatic impairment

• Conditions predisposing to hypoxia (e.g., cardiac or respiratory failure)

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects may include:

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort

• Mild headache

• Hypoglycemia is rare when used without insulin or sulfonylureas

Rare but serious adverse effects include lactic acidosis (primarily due to Metformin), pancreatitis (with Linagliptin), or severe hypersensitivity reactions.

Pregnancy and Lactation

• Safety in pregnancy and lactation has not been fully established

• Use only if clearly needed and under medical supervision

Precautions and Warnings

• Monitor renal and hepatic function regularly

• Adjust dosage in elderly patients or those with renal impairment

• Maintain adequate hydration

• Use caution when co-administered with drugs that may affect renal function or glucose metabolism

Storage Conditions

• Store below 30°C in a dry place

• Protect from light and moisture

• Keep out of reach of children